Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Emergency services search for five people last seen in missing Jeep - 2A Manual for SUVs with Less Noteworthy Gas Mileage
- 3As infant botulism cases climb to 31, recalled ByHeart baby formula is still on some store shelves
- 4I watched the buzzy new AI documentary — and left feeling both hopeful and terrified
- 52024 Manual for Light Extravagance Room Feel: What's Moving
- 2023's Best 10 Cell phone Advancements You Can't Miss
- Dozens of hidden star streams found in the outskirts of our Milky Way galaxy
- When will the Epstein files be released — and will they reveal anything new?
- Vote In favor of Your Favored Shimmering Water
- Scientists detect X-ray glow from interstellar comet 3I/ATLAS extending 250,000 miles into space
- Most loved Seared Chicken: Which Chain Rules?
- Dolly Parton misses Dollywood event due to 'a few health challenges' after skipping honorary Oscars
- ‘And then we saw the little head.’ Scientists witness rare sperm whale birth
- Relentless rise in carbon pollution from fossil fuels slightly dampens climate-fighting hopes
